Tim Evans
Stock Analyst
(n/a)
# 1,782
Out of 4,648 analysts
29
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Tim Evans
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTLT Catalent | Maintains: Equal-Weight | $50 → $42 | $58.69 | -28.44% | 6 | Nov 16, 2023 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $38 → $35 | $317.96 | -88.99% | 3 | Feb 28, 2018 | |
| BIO Bio-Rad Laboratories | Maintains: Outperform | $290 → $280 | $368.92 | -24.10% | 2 | Feb 28, 2018 | |
| BIO.B Bio-Rad Laboratories | Maintains: Outperform | $290 → $280 | $334.85 | -16.38% | 2 | Feb 28, 2018 | |
| ILMN Illumina | Upgrades: Outperform | n/a | $153.49 | - | 2 | Jan 2, 2018 | |
| WST West Pharmaceutical Services | Maintains: Outperform | $105 → $112 | $314.77 | -64.42% | 4 | Oct 27, 2017 | |
| DGX Quest Diagnostics | Maintains: Market Perform | $88 → $86 | $154.33 | -44.28% | 2 | Oct 20, 2017 | |
| LH Labcorp Holdings | Reinstates: Outperform | $175 | $227.17 | -22.97% | 1 | Oct 12, 2017 | |
| TECH Bio-Techne | Initiates: Market Perform | n/a | $75.90 | - | 1 | Jul 13, 2017 | |
| DHR Danaher | Initiates: Market Perform | $90 | $247.18 | -63.59% | 1 | Jul 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1,364.02 | - | 1 | Jul 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $59.35 | - | 2 | Jul 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $139.65 | - | 1 | Jul 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.74 | - | 1 | May 3, 2017 |
Catalent
Nov 16, 2023
Maintains: Equal-Weight
Price Target: $50 → $42
Current: $58.69
Upside: -28.44%
Medpace Holdings
Feb 28, 2018
Maintains: Market Perform
Price Target: $38 → $35
Current: $317.96
Upside: -88.99%
Bio-Rad Laboratories
Feb 28, 2018
Maintains: Outperform
Price Target: $290 → $280
Current: $368.92
Upside: -24.10%
Bio-Rad Laboratories
Feb 28, 2018
Maintains: Outperform
Price Target: $290 → $280
Current: $334.85
Upside: -16.38%
Illumina
Jan 2, 2018
Upgrades: Outperform
Price Target: n/a
Current: $153.49
Upside: -
West Pharmaceutical Services
Oct 27, 2017
Maintains: Outperform
Price Target: $105 → $112
Current: $314.77
Upside: -64.42%
Quest Diagnostics
Oct 20, 2017
Maintains: Market Perform
Price Target: $88 → $86
Current: $154.33
Upside: -44.28%
Labcorp Holdings
Oct 12, 2017
Reinstates: Outperform
Price Target: $175
Current: $227.17
Upside: -22.97%
Bio-Techne
Jul 13, 2017
Initiates: Market Perform
Price Target: n/a
Current: $75.90
Upside: -
Danaher
Jul 13, 2017
Initiates: Market Perform
Price Target: $90
Current: $247.18
Upside: -63.59%
Jul 13, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1,364.02
Upside: -
Jul 13, 2017
Downgrades: Underperform
Price Target: n/a
Current: $59.35
Upside: -
Jul 13, 2017
Upgrades: Outperform
Price Target: n/a
Current: $139.65
Upside: -
May 3, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $1.74
Upside: -